TickrTrends AMGN fair value analysis

Dow Jones Industrial Average — Monthly Report September 2026

thestockmarketwatch.com · 2026-09-09

The Dow enters the back half of September in an awkward position: earnings are running at their strongest rate since 2021, the index is within 3% of an

TickrTrends take: Amgen's inclusion in the Dow Jones Industrial Average reflects its status as a major healthcare company, though TickrTrends currently assesses the stock as overvalued at present levels. For valuation-conscious investors, monitoring whether the company's fundamentals can justify its current market positioning relative to peers in the Healthcare sector will be important in coming months. The monthly performance data from September 2026 provides one data point, but the gap between current valuation and underlying business metrics warrants continued attention.

Read the full story at thestockmarketwatch.com →

Is AMGN undervalued? See TickrTrends' fair value analysis →